Yen FS - Search Results

1

Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes.

Yen FS, Yang YC, Hwu CM, Wei JC, Huang YH, Hou MC, Hsu CC. Yen FS, et al. Liver Int. 2020 May;40(5):1089-1097. doi: 10.1111/liv.14385. Epub 2020 Feb 10. Liver Int. 2020. PMID: 31960563 Free PMC article.

2

A Point-based Mortality Prediction System for Older Adults with Diabetes.

Chang YK, Huang LF, Shin SJ, Lin KD, Chong K, Yen FS, Chang HY, Chuang SY, Hsieh TJ, Hsiung CA, Hsu CC. Chang YK, et al. Among authors: yen fs. Sci Rep. 2017 Oct 4;7(1):12652. doi: 10.1038/s41598-017-12751-3. Sci Rep. 2017. PMID: 28978911 Free PMC article.

3

Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy.

Yen FS, Chiang JH, Pan CW, Lin BJ, Wei JC, Hsu CC. Yen FS, et al. Diabetes Res Clin Pract. 2018 Jun;140:279-287. doi: 10.1016/j.diabres.2018.04.012. Epub 2018 Apr 12. Diabetes Res Clin Pract. 2018. PMID: 29654814

4

Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin.

Hsu PF, Sung SH, Cheng HM, Shin SJ, Lin KD, Chong K, Yen FS, Yu BH, Huang CT, Hsu CC. Hsu PF, et al. Among authors: yen fs. J Clin Endocrinol Metab. 2018 Oct 1;103(10):3611-3619. doi: 10.1210/jc.2018-00040. J Clin Endocrinol Metab. 2018. PMID: 30113697

5

Effects of metformin use on total mortality in patients with type 2 diabetes and chronic obstructive pulmonary disease: A matched-subject design.

Yen FS, Chen W, Wei JC, Hsu CC, Hwu CM. Yen FS, et al. PLoS One. 2018 Oct 4;13(10):e0204859. doi: 10.1371/journal.pone.0204859. eCollection 2018. PLoS One. 2018. PMID: 30286138 Free PMC article.

6

All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes.

Yen FS, Chiang JH, Hwu CM, Yen YH, Lin BJ, Wei JC, Hsu CC. Yen FS, et al. Among authors: yen yh. BMC Endocr Disord. 2019 Jan 5;19(1):3. doi: 10.1186/s12902-018-0330-7. BMC Endocr Disord. 2019. PMID: 30611254 Free PMC article.

7

Pioglitazone Exposure Reduced the Risk of All-Cause Mortality in Insulin-Treated Patients with Type 2 Diabetes Mellitus.

Yen FS, Wang HC, Pan CW, Wei JC, Hsu CC, Hwu CM. Yen FS, et al. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz026. doi: 10.1210/clinem/dgz026. J Clin Endocrinol Metab. 2020. PMID: 31544207

8

Urate-Lowering Therapy May Prevent the Development of Coronary Artery Disease in Patients With Gout.

Yen FS, Hsu CC, Li HL, Wei JC, Hwu CM. Yen FS, et al. Front Med (Lausanne). 2020 Feb 27;7:63. doi: 10.3389/fmed.2020.00063. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32175324 Free PMC article.

9

Urate-lowering therapy exerts protective effects against hypertension development in patients with gout.

Lin KH, Yen FS, Li HL, Wei JC, Hsu CC, Yang CC, Hwu CM. Lin KH, et al. Among authors: yen fs. J Hum Hypertens. 2021 Apr;35(4):351-359. doi: 10.1038/s41371-020-0342-4. Epub 2020 May 4. J Hum Hypertens. 2021. PMID: 32366929

10

Persons with type 2 diabetes and high insulin persistence were associated with a lower risk of mortality: A nationwide retrospective cohort study.

Yen FS, Wei JC, Liu JS, Hsu CC, Hwu CM. Yen FS, et al. J Diabetes Investig. 2021 Feb;12(2):146-154. doi: 10.1111/jdi.13330. Epub 2020 Jul 25. J Diabetes Investig. 2021. PMID: 32569417 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

102 results

Search Page

Filters